Related Experiment Videos
MMP-14 can serve as a prognostic marker in patients with supraglottic cancer
Huiyan Zhang1, Ming Liu, Yanan Sun
1Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated Hospital, Harbin Medical University, 150086, Harbin, People's Republic of China.
Abstract:
The purpose of this study was to examine the expression of MMP-14, 15 and 16 (MT1, MT2 and MT3-MMP) in supraglottic carcinoma and to explore their clinical significance. Expression of MMP-14, 15 and 16 was examined using RT-PCR and immunohistochemistry methods in samples from 85 cases of supraglottic carcinoma. Results showed that both mRNA and protein expression of MMP-14, 15 and 16 were increased in supraglottic carcinoma tissues compared to expression in control adjacent non-neoplastic tissues (P < 0.05). Expression of MMP-14, but not MMP-15 and MMP-16, was significantly increased in the T3 and neck nodal metastasis groups compared with the T1-2 group and the group without nodal metastasis at both mRNA and protein levels (P < 0.05). Expression of MMP-14 mRNA and protein was also higher in tumors of patients with stage III-IV disease compared to patients with clinical stage I-II tumors (P < 0.05). Kaplan-Meier survival curves showed that the groups with high MMP-14 protein expression had a poorer prognosis than patients in the groups with weak or negative expression of MMP-14 protein (P < 0.05). In conclusion, MMP-14 may play an important role in the progression of supraglottic carcinoma and may be a novel prognostic factor for patients with supraglottic carcinoma.
Insights
Matrix metalloproteinase-14 (MMP-14) is elevated in supraglottic carcinoma, correlating with advanced disease and poorer patient prognosis. This suggests MMP-14 may serve as a novel prognostic biomarker for this cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Supraglottic carcinoma is a significant head and neck cancer.
- Matrix metalloproteinases (MMPs) are implicated in tumor progression.
- Specific MMPs, including MMP-14, MT2-MMP, and MT3-MMP, warrant investigation in this context.
Purpose of the Study:
- To investigate the expression of MMP-14, MMP-15 (MT2-MMP), and MMP-16 (MT3-MMP) in supraglottic carcinoma.
- To determine the clinical significance and prognostic value of these MMPs in supraglottic carcinoma.
Main Methods:
- Analysis of 85 supraglottic carcinoma tissue samples.
- Quantitative assessment of MMP-14, MMP-15, and MMP-16 mRNA and protein expression using RT-PCR and immunohistochemistry.
- Correlation of MMP expression with clinical parameters and patient survival.
Main Results:
- Elevated mRNA and protein levels of MMP-14, MMP-15, and MMP-16 were observed in tumor tissues compared to adjacent non-neoplastic tissues.
- MMP-14 expression significantly increased with advanced tumor stage (T3) and lymph node metastasis.
- High MMP-14 protein expression was associated with significantly poorer patient prognosis.
- MMP-15 and MMP-16 expression did not show significant correlation with tumor stage or metastasis.
Conclusions:
- MMP-14 expression is upregulated in supraglottic carcinoma and correlates with disease progression.
- MMP-14 may play a crucial role in the development and advancement of supraglottic tumors.
- MMP-14 emerges as a potential novel prognostic biomarker for patients diagnosed with supraglottic carcinoma.
